Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott D Edmondson

Showing results (1-10 of 44) with videos related to

Pageof 5
Sort By:
Journal of Medicinal Chemistry|October 8, 2024
Discovery of the First Clinical Protein Degrader for the Treatment of Autoimmune Indications: Orally Bioavailable and Selective IRAK4 Degrader KT-474Scott D Edmondson
Angewandte Chemie (International Ed. in English)|May 2, 2018
The Total Synthesis of Spirotryprostatin AScott D Edmondson, Samuel J Danishefsky
Bioorganic & Medicinal Chemistry Letters|May 4, 2019
Proteolysis targeting chimeras (PROTACs) in 'beyond rule-of-five' chemical space: Recent progress and future challengesScott D Edmondson, Bin Yang, Charlene Fallan
The Journal of Organic Chemistry|October 25, 2001
Studies Directed toward the Synthesis of the Unusual Antileukemic Diterpene Jatrophatrione. 2. Functionalization of Advanced Polycyclic Precursors to the 9-Epi and 8,9-Dehydro CongenersLeo A. Paquette, Scott D. Edmondson, Nathaniel Monck, et al.
The Journal of Organic Chemistry|October 25, 2001
Studies Directed toward the Synthesis of the Unusual Antileukemic Diterpene Jatrophatrione. 1. A Solution to the Problem of Chirality Merger during Elaboration of the Entire Carbotricyclic FrameworkLeo A. Paquette, Shogo Nakatani, Thomas M. Zydowsky, et al.
Acta Crystallographica. Section D, Biological Crystallography|December 20, 2003
Crystallization and preliminary X-ray diffraction analysis of the catalytic domain of recombinant human phosphodiesterase 3BSangita B Patel, Jeffrey P Varnerin, Michael R Tota, et al.
Journal of Medicinal Chemistry|August 18, 2020
Discovery of Proteolysis-Targeting Chimera Molecules that Selectively Degrade the IRAK3 PseudokinaseSébastien L Degorce, Omid Tavana, Erica Banks, et al.
Bioorganic & Medicinal Chemistry Letters|April 16, 2011
Discovery of pyrimidine carboxamides as potent and selective CCK1 receptor agonistsLiping Wang, James A Hubert, Susan J Lee, et al.
Biochemistry|May 19, 2004
Crystal structure of human phosphodiesterase 3B: atomic basis for substrate and inhibitor specificityGiovanna Scapin, Sangita B Patel, Christine Chung, et al.
Bioorganic & Medicinal Chemistry Letters|June 15, 2007
Discovery of 3-aminopiperidines as potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitorsJason M Cox, Bart Harper, Anthony Mastracchio, et al.
Pageof 5

Showing results (1-10 of 44) with videos related to

Sort By:
Pageof 5
Journal of Medicinal Chemistry|October 8, 2024
Discovery of the First Clinical Protein Degrader for the Treatment of Autoimmune Indications: Orally Bioavailable and Selective IRAK4 Degrader KT-474Scott D Edmondson
Angewandte Chemie (International Ed. in English)|May 2, 2018
The Total Synthesis of Spirotryprostatin AScott D Edmondson, Samuel J Danishefsky
Bioorganic & Medicinal Chemistry Letters|May 4, 2019
Proteolysis targeting chimeras (PROTACs) in 'beyond rule-of-five' chemical space: Recent progress and future challengesScott D Edmondson, Bin Yang, Charlene Fallan
The Journal of Organic Chemistry|October 25, 2001
Studies Directed toward the Synthesis of the Unusual Antileukemic Diterpene Jatrophatrione. 2. Functionalization of Advanced Polycyclic Precursors to the 9-Epi and 8,9-Dehydro CongenersLeo A. Paquette, Scott D. Edmondson, Nathaniel Monck, et al.
The Journal of Organic Chemistry|October 25, 2001
Studies Directed toward the Synthesis of the Unusual Antileukemic Diterpene Jatrophatrione. 1. A Solution to the Problem of Chirality Merger during Elaboration of the Entire Carbotricyclic FrameworkLeo A. Paquette, Shogo Nakatani, Thomas M. Zydowsky, et al.
Acta Crystallographica. Section D, Biological Crystallography|December 20, 2003
Crystallization and preliminary X-ray diffraction analysis of the catalytic domain of recombinant human phosphodiesterase 3BSangita B Patel, Jeffrey P Varnerin, Michael R Tota, et al.
Journal of Medicinal Chemistry|August 18, 2020
Discovery of Proteolysis-Targeting Chimera Molecules that Selectively Degrade the IRAK3 PseudokinaseSébastien L Degorce, Omid Tavana, Erica Banks, et al.
Bioorganic & Medicinal Chemistry Letters|April 16, 2011
Discovery of pyrimidine carboxamides as potent and selective CCK1 receptor agonistsLiping Wang, James A Hubert, Susan J Lee, et al.
Biochemistry|May 19, 2004
Crystal structure of human phosphodiesterase 3B: atomic basis for substrate and inhibitor specificityGiovanna Scapin, Sangita B Patel, Christine Chung, et al.
Bioorganic & Medicinal Chemistry Letters|June 15, 2007
Discovery of 3-aminopiperidines as potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitorsJason M Cox, Bart Harper, Anthony Mastracchio, et al.
Pageof 5